

Jesus M Banales

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4896725/jesus-m-banales-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

6,161
citations

43
h-index

74
g-index

185
ext. papers

8,508
ext. citations

8.4
avg. IF

5.69
L-index

#	Paper	IF	Citations
163	Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis.. <i>Nature Communications</i> , 2022 , 13, 1096	17.4	2
162	DHEA Protects Human Cholangiocytes and Hepatocytes against Apoptosis and Oxidative Stress.. <i>Cells</i> , 2022 , 11,	7.9	2
161	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022 , 14, 2389	6.6	2
160	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. <i>Journal of Hepatology</i> , 2021 ,	13.4	10
159	p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications. <i>Scientific Reports</i> , 2021 , 11, 21649	4.9	1
158	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021 , 73, 103661	8.8	4
157	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021 , 70, 2359-2372	19.2	10
156	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021 , 73, 2311-2325	11.2	13
155	Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. <i>Gut</i> , 2021 , 70, 342-356	19.2	9
154	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 73, 2380-2396	11.2	3
153	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 2021 ,		5
152	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
151	Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 371-372	24.2	1
150	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
149	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. <i>Cell Stem Cell</i> , 2021 , 28, 816-832	18	32
148	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021 , 13,	6.6	3
147	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. <i>Frontiers in Medicine</i> , 2021 , 8, 683250	4.9	7

146	Reply to: "We need to talk about #livertwitter". <i>Journal of Hepatology</i> , 2021 , 75, 1240-1241	13.4	
145	Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. <i>United European Gastroenterology Journal</i> , 2021 , 9, 848	5.3	1
144	Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. <i>Hepatology</i> , 2021 , 74, 2007-2020	11.2	6
143	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. <i>Hepatology</i> , 2021 , 73, 186-203	11.2	1
142	Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor- β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. <i>Gastroenterology</i> , 2021 , 160, 889-905.e10	13.3	5
141	Pathogenesis of Cholangiocarcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021 , 16, 433-463	13.4	16
140	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. <i>Journal of Hepatology</i> , 2021 , 74, 394-406	13.4	2
139	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021 , 74, 20-30	13.4	24
138	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021 , 70, 1345-1361	19.2	20
137	Primary biliary cholangitis: pathogenic mechanisms. <i>Current Opinion in Gastroenterology</i> , 2021 , 37, 91-98	3	1
136	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 377-388	5.9	2
135	Optimizing the use of twitter for research dissemination: The "Three Facts and a Story" randomized-controlled trial. <i>Journal of Hepatology</i> , 2021 , 75, 271-274	13.4	5
134	REPLY. <i>Hepatology</i> , 2021 , 74, 1129-1131	11.2	1
133	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. <i>Journal of Hepatology</i> , 2021 , 75, 363-376	13.4	2
132	REPLY. <i>Hepatology</i> , 2021 , 74, 2319-2321	11.2	0
131	Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling. <i>Hepatology</i> , 2021 , 74, 3194-3212	11.2	6
130	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. <i>Liver Cancer</i> , 2021 , 10, 545-560	9.1	1
129	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. <i>American Journal of Pathology</i> , 2021 , 191, 1651-1667	5.8	2

128	Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region. <i>International Journal of Infectious Diseases</i> , 2021 , 110, 114-122	10.5	0
127	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
126	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021 , 53, 101275	8.8	2
125	Long Non-Coding RNA ACTA2-AS1 Promotes Ductular Reaction by Interacting with the p300/ELK1 Complex.. <i>Journal of Hepatology</i> , 2021 ,	13.4	3
124	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. <i>Cancers</i> , 2020 , 12,	6.6	1
123	Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
122	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020 , 40, 1670-1685	7.9	7
121	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	11
120	Lignins from Agroindustrial by-Products as Natural Ingredients for Cosmetics: Chemical Structure and In Vitro Sunscreen and Cytotoxic Activities. <i>Molecules</i> , 2020 , 25,	4.8	23
119	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020 , 73, 17-25	13.4	26
118	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020 , 9,	7.9	34
117	Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. <i>Cells</i> , 2020 , 9,	7.9	22
116	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
115	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. <i>Cancers</i> , 2020 , 12,	6.6	15
114	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. <i>Liver International</i> , 2020 , 40, 3103-3116	7.9	10
113	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools 2020 , 157-180		
112	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH 2020 , 225-236		
111	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020 , 52, 1430-1442	3.3	15

110	MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. <i>Hepatology</i> , 2020 , 72, 949-964	11.2	11
109	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. <i>Digestive and Liver Disease</i> , 2020 , 52, 1282-1293	3.3	21
108	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1047-1059	8.7	23
107	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). <i>Cancers</i> , 2020 , 12,	6.6	7
106	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl-Induced Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
105	miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis. <i>Journal of Pathology</i> , 2020 , 252, 239-251	9.4	9
104	Novel GANAB variants associated with polycystic liver disease. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 302	4.2	3
103	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
102	Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. <i>Hepatology</i> , 2020 , 71, 583-599	11.2	32
101	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019 , 105, 102328	15.5	45
100	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 497-511	24.2	38
99	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 1492-1500	1.5	24
98	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 2246-2256	6.9	7
97	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. <i>Cell Death and Differentiation</i> , 2019 , 26, 2710-2726	12.7	11
96	Cholangiocyte pathobiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 269-281	24.2	155
95	Diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 108-123	1.2	53
94	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. <i>Hepatology</i> , 2019 , 70, 1246-1261	11.2	30
93	Adaptive downregulation of Cl-/HCO3- exchange activity in rat hepatocytes under experimental obstructive cholestasis. <i>PLoS ONE</i> , 2019 , 14, e0212215	3.7	2

92	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. <i>Gastroenterology</i> , 2019 , 156, 1190-1205.e14	13.3	10
91	Genetics of polycystic liver diseases. <i>Current Opinion in Gastroenterology</i> , 2019 , 35, 65-72	3	14
90	Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes. <i>Hepatology</i> , 2019 , 69, 817-830	11.2	20
89	Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 587-603	11.2	56
88	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019 , 189, 2090-2101	5.8	14
87	Metabolic rearrangements in primary liver cancers: cause and consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 748-766	24.2	54
86	Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. <i>Hepatology</i> , 2019 , 69, 699-716	11.2	21
85	Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. <i>Liver International</i> , 2019 , 39, 575-582	7.9	11
84	Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury. <i>Hepatology</i> , 2019 , 70, 883-898	11.2	8
83	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. <i>British Journal of Pharmacology</i> , 2019 , 176, 787-800	8.6	30
82	Wnt- β -catenin signalling in liver development, health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 121-136	24.2	156
81	Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018. <i>Hepatology Communications</i> , 2019 , 3, 305-315	6	10
80	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019 , 70, 547-562	11.2	54
79	MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. <i>Hepatology</i> , 2018 , 68, 561-573	11.2	37
78	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. <i>Hepatology</i> , 2018 , 67, 1420-1440	11.2	45
77	Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 1335-1344	6.9	39
76	High fluorescence cell count in ascitic body fluids for carcinomatosis screening. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 272-274	5.9	6
75	Fibrocystic Diseases of the Liver 2018 , 995-1014.e6		

74	Clinical management of polycystic liver disease. <i>Journal of Hepatology</i> , 2018 , 68, 827-837	13.4	60
73	miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. <i>Cell Death and Differentiation</i> , 2018 , 25, 857-872	12.7	71
72	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 1468-1477	6.9	49
71	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2018 , 9, 958	9.8	28
70	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1260-1270	6.1	43
69	Extracellular Vesicles in Hepatobiliary Malignancies. <i>Frontiers in Immunology</i> , 2018 , 9, 2270	8.4	15
68	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. <i>Journal of Hepatology</i> , 2018 , 69, 1371-1383	13.4	21
67	Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018 , 68, S72-S73	13.4	4
66	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018 , 2, 807-820	6	64
65	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 72-83	13.4	57
64	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 282-292	13.4	85
63	Novel lncRNA T-UCR as a potential downstream driver of the Wnt/ β -catenin pathway in hepatobiliary carcinogenesis. <i>Gut</i> , 2017 , 66, 1177-1178	19.2	13
62	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. <i>Digestive Diseases</i> , 2017 , 35, 275-281	3.2	5
61	Nlrp3 Activation Induces IL-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes. <i>American Journal of Pathology</i> , 2017 , 187, 366-376	5.8	23
60	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017 , 66, 1125-1143	11.2	148
59	Genetics: Novel causative genes for polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 391-392	24.2	10
58	Reply to: "Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2017 ,	13.4	
57	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1430-1439	1.5	72

56	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , 2017 , 66, 102-115	13.4	91
55	New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets. <i>Current Drug Targets</i> , 2017 , 18, 908-920	3	4
54	Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy. <i>Current Drug Targets</i> , 2017 , 18, 932-949	3	4
53	Effect of pravastatin on the survival of patients with advanced gastric cancer. <i>Oncotarget</i> , 2016 , 7, 4379-34	3.4	9
52	Mutations in GANAB, Encoding the Glucosidase III β Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. <i>American Journal of Human Genetics</i> , 2016 , 98, 1193-1207	11	240
51	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 15-27	2.4	16
50	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 1838-1846	3	44
49	Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. <i>Liver International</i> , 2016 , 36, 1370-7	7.9	27
48	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016 , 65, 1535-45	19.2	62
47	Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. <i>Journal of Hepatology</i> , 2016 , 65, 601-7	13.4	26
46	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 261-80	24.2	618
45	Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. <i>Journal of Biological Chemistry</i> , 2015 , 290, 184-96	5.4	51
44	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. <i>Journal of Hepatology</i> , 2015 , 63, 952-61	13.4	44
43	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). <i>Journal of Controlled Release</i> , 2015 , 216, 93-102	11.7	24
42	Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. <i>Hepatology</i> , 2015 , 62, 1237-48	11.2	25
41	Measurement of liver iron concentration by MRI is reproducible. <i>BioMed Research International</i> , 2015 , 2015, 294024	3	10
40	Bile Acids in Physiology, Pathology and Pharmacology. <i>Current Drug Metabolism</i> , 2015 , 17, 4-29	3.5	83
39	Methods for extracellular vesicles isolation in a hospital setting. <i>Frontiers in Immunology</i> , 2015 , 6, 50	8.4	75

38	Functional crosstalk between the adenosine transporter CNT3 and purinergic receptors in the biliary epithelia. <i>Journal of Hepatology</i> , 2014 , 61, 1337-43	13.4	9
37	Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. <i>Molecular Cancer Research</i> , 2014 , 12, 91-100	6.6	50
36	Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. <i>Liver International</i> , 2014 , 34, e257-70	7.9	37
35	Polycystic liver diseases: advanced insights into the molecular mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 750-61	24.2	61
34	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. <i>BMC Medicine</i> , 2014 , 12, 137	11.4	15
33	Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. <i>American Journal of Pathology</i> , 2014 , 184, 110-21	5.8	14
32	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. <i>Gut</i> , 2014 , 63, 1658-67	19.2	42
31	Anion exchanger 2 is critical for CD8(+) T _H 1 cells to maintain pH _i homeostasis and modulate immune responses. <i>European Journal of Immunology</i> , 2014 , 44, 1341-51	6.1	22
30	Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. <i>Hepatology</i> , 2014 , 60, 1324-35	11.2	17
29	MicroRNAs and cholestatic liver diseases. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 303-9	3	28
28	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. <i>Hepatology</i> , 2013 , 58, 409-21	11.2	74
27	MicroRNAs in Liver Diseases 2013 , 509-522		1
26	Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. <i>Hepatology</i> , 2013 , 58, 1065-73	11.2	102
25	Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure. <i>PLoS ONE</i> , 2013 , 8, e52683	3.7	5
24	Somatic second-hit mutations leads to polycystic liver diseases. <i>World Journal of Gastroenterology</i> , 2013 , 19, 141-3	5.6	9
23	The significance of genetics for cholangiocarcinoma development. <i>Annals of Translational Medicine</i> , 2013 , 1, 28	3.2	16
22	Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. <i>Cancer Cell International</i> , 2012 , 12, 5	6.4	5
21	MicroRNAs in biliary diseases. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6189-96	5.6	24

20	Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. <i>Gastroenterology</i> , 2012 , 142, 622-633.e4	13.3	31
19	Up-regulation of microRNA 506 leads to decreased Cl-/HCO ₃ - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012 , 56, 687-97	11.2	160
18	Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. <i>PLoS ONE</i> , 2011 , 6, e28717	3.7	28
17	Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, G990-9	5.1	187
16	Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. <i>Gastroenterology</i> , 2010 , 139, 304-14.e2	13.3	72
15	Bicarbonate secretion of mouse cholangiocytes involves Na(+)-HCO ₃ (-) cotransport in addition to Na(+)-independent Cl(-)/HCO ₃ (-) exchange. <i>Hepatology</i> , 2010 , 51, 891-902	11.2	33
14	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. <i>Hepatology</i> , 2010 , 52, 667-77	11.2	15
13	Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2 ^{-/-} mice. <i>PLoS ONE</i> , 2010 , 5, e15690	3.7	18
12	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). <i>Hepatology</i> , 2009 , 49, 160-74	11.2	95
11	Primers on molecular pathways - ion channels: key regulators of pancreatic physiology. <i>Pancreatology</i> , 2009 , 9, 556-9	3.8	2
10	Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. <i>Gastroenterology</i> , 2008 , 134, 1482-93	13.3	159
9	Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. <i>American Journal of Pathology</i> , 2008 , 173, 1637-46	5.8	58
8	Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y ₁₂ purinergic receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, G725-34	5.1	125
7	MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3714-24	15.9	133
6	Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19138-43	11.5	164
5	Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. <i>Hepatology</i> , 2006 , 43, 266-75	11.2	79
4	Cholangiocyte anion exchange and biliary bicarbonate excretion. <i>World Journal of Gastroenterology</i> , 2006 , 12, 3496-511	5.6	96
3	Shared apical sorting of anion exchanger isoforms AE2a, AE2b1, and AE2b2 in primary hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 319, 1040-6	3.4	36

- | | | |
|---|---|---|
| 2 | Development of new assays and improved procedures for the purification of recombinant human chymase. <i>FEBS Journal</i> , 2001 , 268, 5885-93 | 5 |
| 1 | rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and histological severity of NAFLD: a meta-analysis | 3 |